In This Article:
Apple (AAPL)
Investors were not impressed by Apple’s 2024 Worldwide Developers Conference (WWDC), where the tech giant unveiled 'Apple Intelligence' — a suite of new generative AI features set to be included in iOS 18, iPadOS 18 and macOS Sequoia later this year.
The stock was lower in pre-market trading after finishing the session in the red as the iPhone maker tried to show worried investors that it is not slipping behind on AI.
As part of its generative AI announcements on Monday, Apple said that alongside its new Apple Intelligence system that will allow users to access generative AI-powered tools almost anywhere within their devices, it would give users the option to send a query to ChatGPT to take advantage of its own spectrum of knowledge.
Read more: FTSE 100 LIVE: European stock markets subdued as UK unemployment rate rises to 4.4%
However, billionaire Elon Musk has threatened to ban the use of Apple devices at his companies if Apple integrates OpenAI’s ChatGPT into its iPhone, iPad and Mac operating systems.
“If Apple integrates OpenAI at the OS level, then Apple devices will be banned at my companies. That is an unacceptable security violation,” Musk said on X.
“They’re selling you down the river. Apple using the words ‘protect your privacy’ while handing your data over to a third-party AI that they don’t understand and can’t themselves create is *not* protecting privacy at all,” he added.
Eli Lilly (LLY)
Shares in the pharma company were higher ahead of the market's opening as its Alzheimer's drug secured unanimous backing from an outside US Food and Drug Administration panel.
The experts concluded, by an 11-0 vote, that the drug’s benefits outweigh its risks, despite some safety concerns.
“I thought the evidence is very strong and the trials [show] the effectiveness of the drug,” said Dean Follman, a panellist and assistant director of biostatistics at the National Institute of Allergy and Infectious Diseases.
The panel said the medicine, developed by Eli Lilly and known as donanemab, appeared to be an effective treatment for certain Alzheimer’s patients.
The FDA isn’t required to follow the recommendations of its advisory committees, but it typically does.